REGN Form 4 reports multiple insider transactions
Pitofsky Jason reported multiple insider transaction types in a Form 4 filing for REGN.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Pitofsky Jason reported multiple insider transaction types in a Form 4 filing for REGN. The filing lists transactions totaling 4,036 shares at a weighted average price of $684.14 per share. Following the reported transactions, holdings were 4,272 shares.
Insider Trade Summary
Exercise and sale activity reported; no spread calculated
Exercise and Sale
15 txns
Insider
Pitofsky Jason
Role
SVP Controller
Sold
2,036 shs ($1.59M)
Approx. gross sale proceeds
$1.59M
Approx. exercise cost
$492K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Non-Qualified Stock Option (right to buy) | 1,000 | $0.00 | $0.00 |
| Exercise | Common Stock | 1,000 | $492.00 | $492K |
| Sale | Common Stock | 20 | $775.95 | $16K |
| Sale | Common Stock | 521 | $776.43 | $405K |
| Sale | Common Stock | 391 | $777.51 | $304K |
| Sale | Common Stock | 563 | $778.35 | $438K |
| Sale | Common Stock | 205 | $779.56 | $160K |
| Sale | Common Stock | 75 | $780.06 | $59K |
| Sale | Common Stock | 26 | $781.37 | $20K |
| Sale | Common Stock | 37 | $782.67 | $29K |
| Sale | Common Stock | 144 | $783.23 | $113K |
| Sale | Common Stock | 1 | $784.66 | $784.66 |
| Sale | Common Stock | 53 | $785.72 | $42K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Non-Qualified Stock Option (right to buy) — 905 contracts (Direct);
Common Stock — 4,272 shares (Direct);
Common Stock — 31 shares (Indirect, By 401(k) Plan);
Common Stock — 179 shares (Indirect, by Spouse)
Footnotes (11)
- F1. Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on November 10, 2025.
- F2. Represents volume-weighted average price of sales of 521 shares of Company stock on February 9, 2026 at prices ranging from $776.05 to $776.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price.
- F3. Represents volume-weighted average price of sales of 391 shares of Company stock on February 9, 2026 at prices ranging from $777.33 to $777.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price.
- F4. Represents volume-weighted average price of sales of 563 shares of Company stock on February 9, 2026 at prices ranging from $778.00 to $778.95. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price.
- F5. Represents volume-weighted average price of sales of 205 shares of Company stock on February 9, 2026 at prices ranging from $779.19 to $779.96. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price.
- F6. Represents volume-weighted average price of sales of 75 shares of Company stock on February 9, 2026 at prices ranging from $780.03 to $780.65. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price.
- F7. Represents volume-weighted average price of sales of 26 shares of Company stock on February 9, 2026 at prices ranging from $781.18 to $781.53. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price.
- F8. Represents volume-weighted average price of sales of 37 shares of Company stock on February 9, 2026 at prices ranging from $782.22 to $782.83. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price.
- F9. Represents volume-weighted average price of sales of 144 shares of Company stock on February 9, 2026 at prices ranging from $783.17 to $783.29. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price.
- F10. Represents volume-weighted average price of sales of 53 shares of Company stock on February 9, 2026 at prices ranging from $785.72 to $785.73. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2026 at each separate price.
- F11. The stock option award vested in four equal annual installments, commencing one year after the date of grant.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Regeneron (REGN) report for Jason Pitofsky?
Regeneron disclosed that SVP Controller Jason Pitofsky exercised a non-qualified stock option for 1,000 common shares at $492 per share and then sold multiple small blocks of common stock in open-market transactions around $776–$786 per share on February 9, 2026 under a Rule 10b5-1 plan.
What stock option activity involving Regeneron (REGN) did the Form 4 show?
The Form 4 shows Jason Pitofsky exercised a non-qualified stock option covering 1,000 shares of Regeneron common stock at a $492 exercise price. The option award vests in four equal annual installments beginning one year after grant, and 905 derivative securities remained beneficially owned after the transaction.
Were Jason Pitofsky’s Regeneron stock sales under a Rule 10b5-1 plan?
Yes. A footnote states that the dispositions and acquisition were made under a trading plan intended to comply with Rule 10b5-1(c), which was adopted on November 10, 2025. Such plans pre-schedule trades to help insiders diversify while managing potential trading-related concerns.
What prices did Jason Pitofsky receive for his Regeneron stock sales?
The reported open-market sales occurred at various volume-weighted average prices, generally around $775.95 to $785.72 per share. Footnotes explain that each average reflects multiple trades within narrow intraday price ranges and that full price-by-trade details are available upon request to the reporting person.
What is the role of Jason Pitofsky at Regeneron Pharmaceuticals?
Jason Pitofsky is identified as an officer of Regeneron Pharmaceuticals with the title "SVP Controller." This senior finance role makes him a Section 16 reporting person, requiring disclosure of his transactions in Regeneron equity securities on Form 4 under U.S. securities regulations.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates